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Commensal bacteria impact host health and immu-
nity through various mechanisms, including the pro-
duction of immunomodulatory molecules. Bacter-
oides fragilis produces a capsular polysaccharide
(PSA), which induces regulatory T cells and mucosal
tolerance. However, unlike pathogens, which employ
secretion systems, the mechanisms by which
commensal bacteria deliver molecules to the host
remain unknown. We reveal that Bacteroides fragilis
releases PSA in outer membrane vesicles (OMVs)
that induce immunomodulatory effects and prevent
experimental colitis. Dendritic cells (DCs) sense
OMV-associated PSA through TLR2, resulting in
enhanced regulatory T cells and anti-inflammatory
cytokine production. OMV-induced signaling in
DCs requires growth arrest and DNA-damage-induc-
ible protein (Gadd45a). DCs treated with PSA-
containing OMVs prevent experimental colitis,
whereas Gadd45a/ DCs are unable to promote
regulatory T cell responses or suppress proinflam-
matory cytokine production and host pathology.
These findings demonstrate that OMV-mediated
delivery of a commensal molecule prevents disease,
uncovering a mechanism of interkingdom communi-
cation between the microbiota and mammals.
INTRODUCTION
Microbes have evolved complex adaptations to inhabit and
replicate in numerous ecological niches on Earth. Animals are
no exception and provide an ideal environment for both transient
and permanent microbial colonization. Many pathogens cause
acute infections as a means to propagate and disseminate,
and accordingly have developed myriad mechanisms to avoid,
subvert, and/or prevent host immune responses. Conversely to
pathogens, symbiotic bacteria have taken a different evolu-
tionary route to promote bacterial replication. The gastrointes-
tinal tract of mammals is colonized for life with a diverseCell Hostcommensal microbiota that provides essential benefits to the
host such as nutrient and caloric extraction from food, develop-
ment of the immune system, and protection from immunologic
and metabolic diseases (Round and Mazmanian, 2009). The
dichotomy between beneficial and harmful microbes is illus-
trated by studies showing that gut colonization by themicrobiota
inhibits infection by enteric pathogens (Chung et al., 2012).
Therefore, unlike most pathogens that acutely infect animals
for days or weeks, symbiotic bacteria have evolved to improve
host health, providing themselves a protected niche where
they flourish for decades.
How do bacteria establishmolecular communication with their
hosts to promote microbial replication? In addition to the export
of single proteins (such as toxins) by the general secretory
pathway, Gram-negative bacteria have evolved intricate mecha-
nisms that can deliver a concert of microbial molecules to
the host. Well-studied examples include type III secretion
systems (T3SSs), T4SS, and T6SS, which assemble macromo-
lecular surface appendages that translocate bacterial effectors
following direct contact with host cells (Galan, 2009). In addition,
outer membrane vesicles (OMVs) are released from the surface
of bacteria and deliver a suite of molecular cargo to target cells.
OMVs from pathogens transport molecules to animal, plant, and
other bacterial cells (Mashburn-Warren and Whiteley, 2006).
Consequently, a fundamental difference between surface secre-
tion systems and OMVs is the distance that microbial molecules
can travel. As commensal bacteria generally do not make inti-
mate contact with host cells, OMVs appear to provide a suitable
mechanism for members of the microbiota to deliver molecules
to distant targets in the host.
Of the numerous microbial species that inhabit the gastroin-
testinal tract of mammals, Bacteroidetes are the most abundant
Gram-negative bacterial phylum (Ley et al., 2008). Bacteroides
fragilis is a commensal that aids in host health by ameliorating
inflammatory bowel disease (IBD) and multiple sclerosis (MS)
in animal models (Mazmanian et al., 2008; Ochoa-Reparaz
et al., 2010a, 2010b). Polysaccharide A (PSA) is an immunomod-
ulatorymolecule produced byB. fragilis that is required and suffi-
cient for treatment of experimental diseases. B. fragilis protects
animals by inducing the development of interlekin-10 (IL-10)-
producing CD4+Foxp3+ regulatory T cells (TREGS) that suppress
inflammation (Ochoa-Reparaz et al., 2010b; Round and Mazma-
nian, 2010). By promoting TREG development, PSA suppresses& Microbe 12, 509–520, October 18, 2012 ª2012 Elsevier Inc. 509
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a potential candidate therapy for IBD and MS. Moreover, the
production of PSA suppresses intestinal immunity directed
toward B. fragilis during normal homeostatic colonization of
animals (Round et al., 2011). Thus PSA promotes mutualism by
providing benefits to both microbe and mammals during symbi-
osis. However, the mechanism by which B. fragilis delivers PSA
to the immune system remains unknown.
Since the genome of B. fragilis does not encode for known
secretion system genes (Cerdeno-Tarraga et al., 2005) and
PSA is a large capsular polysaccharide (Mazmanian et al.,
2005), we reasoned that PSA may be delivered to the immune
system by OMVs. We show herein that PSA is selectively pack-
aged in OMVs that are released by B. fragilis. In vivo, OMVs
containing PSA prevent experimental colitis by suppressing
tumor necrosis factor (TNFa) production and T-helper 17
(Th17) cell development, unlike OMVs that do not contain PSA.
OMVs are internalized into dendritic cells (DCs) and program
DCs to induce the differentiation of IL-10-producing TREG cells
in a PSA-dependent manner. In vitro, TREGS induced by OMVs
are functionally suppressive and inhibit T cell proliferation. We
recently showed that toll-like receptor 2 (TLR2) expression by
T cells promotes TREG function in response to purified PSA
(Round et al., 2011). Here, we reveal that TLR2 expression by
DCs, and not T cells, is required for recognition of PSA within
OMVs. Gene expression profiling led to identification of the
growth arrest and DNA-damage-inducible protein (Gadd45a)
as being required for PSA-mediated TLR2 signaling in DCs.
The transfer of OMV-treated DCs to mice induced for colitis
protects from disease, demonstrating a critical function for
DCs in promoting PSA activity. Gadd45a deletion in DCs abro-
gates IL-10 induction by PSA, and Gadd45a/ DCs are unable
to provide protection from experimental colitis. Our findings
show that delivery of PSA by OMVs underlies the probiotic prop-
erties of B. fragilis, revealing a unique mechanism by which the
commensal microbiota communicates with the immune system
during host-bacterial mutualism.
RESULTS
PSA Is Packaged into Outer Membrane Vesicles
OMVs have been observed in many Gram-negative bacteria. For
Bacteroides fragilis, OMVs are mostly produced by a subset of
bacteria, known as the electron-dense layer (EDL), which
comprises <5% of the population in laboratory culture (Patrick
et al., 1996). We imaged negatively stained EDL-enriched
bacteria by transmission electron microscopy. OMVs were
abundantly produced by B. fragilis (Figure 1A), and could be
observed budding from the bacterial envelope (Figure 1A, higher
magnification). Previous studies have shown that deletion of PSA
abrogates the immunomodulatory capacity of B. fragilis (Maz-
manian et al., 2005, 2008). Electron micrographs of a PSA
mutant strain (B. fragilisDPSA) illustrated no defect in OMV
production, and the size, shape, and abundance of OMVs
produced were indistinguishable from wild-type bacteria (Fig-
ure 1A and Figure S1A). To determine if PSA is associated with
OMVs of B. fragilis, we purified vesicles and probed vesicle
extracts with antisera specific for PSA. OMVs from wild-type
bacteria displayed immunoreactivity to PSA, unlike OMVs from510 Cell Host & Microbe 12, 509–520, October 18, 2012 ª2012 ElsevB. fragilisDPSA, confirming antibody specificity (Figure 1B). In
addition to PSA, B. fragilis produces at least seven other
capsular polysaccharides that coat the surface of bacterial cells
(Krinos et al., 2001; Liu et al., 2008). While PSB was also de-
tected in vesicle preparations, PSG was absent, possibly sug-
gesting regulation of polysaccharide packaging into OMVs
(Figure 1B). Immunogold labeling of purified vesicles confirmed
that PSA is physically associated with OMVs (Figure 1C). To
verify that the absence of PSA did not alter the molecular
composition of vesicles, we performed proteomic analysis by
mass spectrometry that showed negligible differences in the
protein composition between vesicles from wild-type or PSA
mutant bacteria (Figure S1B). Together, these findings reveal
thatB. fragilis packages PSA into OMVs, potentially representing
a mechanism to deliver immunomodulatory signals to its
mammalian host.
OMVs Containing PSA Protect Animals from
Experimental Colitis
Crohn’s disease and ulcerative colitis (forms of IBD) are painful
and medically incurable illnesses of the digestive system (Xavier
and Podolsky, 2007). PSA has been shown to protect and treat
colitis in animal models (Mazmanian et al., 2008; Round and
Mazmanian, 2010), including intestinal inflammation induced
by 2,4,6-trinitrobenzene sulfonic acid (TNBS) (Wirtz et al.,
2007). To investigate if OMVs have therapeutic activity, we orally
treated mice with vesicles containing PSA during experimental
colitis. Control animals rapidly lost weight following rectal
administration of TNBS (Figure 2A; PBS+TNBS) and did not
recover compared to vehicle-treated mice that lost minimal
weight (Figure 2A; PBS+EtOH). Remarkably, OMVs given orally
to TNBS animals significantly protected from weight loss
(Figure 2A; WT-OMV+TNBS). Importantly, when OMVs from
B. fragilisDPSA were administered, weight loss was indistin-
guishable from that in TNBS-treated animals (Figure 2A; DPSA-
OMV+TNBS), demonstrating that PSA is responsible for pre-
venting wasting disease. Reduction in colon length is a hallmark
of TNBS colitis (Ishiguro et al., 2006). Measurements of intact
colons (resected from cecum to rectum) showed normal intes-
tinal lengths in animals treated with PSA-containing vesicles,
but not OMVs lacking PSA (Figure 2B). These results show that
oral feeding of OMVs corrects weight loss and gross pathology
of the colon in a preclinical model of IBD.
IBD in humans, and colitis in animals, features inflammation
driven by innate immune cells and CD4+ T cells, resulting in
severe intestinal pathology (epithelial hyperplasia, submucosal
thickening, infiltration of leukocytes) (Xavier and Podolsky,
2007). TNFa causes damage to the epithelium and disrupts
barrier function, and IL-17 promotes neutrophil migration into
the gut, mediating tissue damage. In contrast, IL-10 is protective
in numerous animal models of colitis (Lindsay et al., 2002),
and PSA requires IL-10 expression during protection from
disease (Round and Mazmanian, 2010). TNFa and IL-17 levels
were elevated in colonic tissues, and CD4+ T cells from the
mesenteric lymph nodes (MLNs) and colons of TNBS-treated
animals; WT-OMVs suppressed proinflammatory cytokines
and enhanced IL-10 production compared to DPSA-OMVs
(Figures S2A–S2C), although these trends did not reach statis-
tical significance. Upon histological analysis of colonic tissues,ier Inc.
ΔΔ
Δ Δ Δ Δ Δ
Δ
A
B C
Figure 1. Outer Membrane Vesicles from Bacteroides fragilis Contain PSA
(A) Transmission electron microscopy of electron-dense layer (EDL)-enriched B. fragilis (WT-OMV) and B. fragilisDPSA (DPSA-OMV) reveals vesicles budding
from the bacterial surface.
(B) Immunoblot analysis of whole-cell (WC) and OMV extracts of bacteria show that PSA and PSB are associated with vesicles, while PSG is only found
associated with the bacterial cell. Deletion mutants for PSA (DPSA), PSB (DPSB), and PSG (DPSG) confirm specificity of each antisera.
(C) Immunogold labeling of purified OMVs, stained with anti-PSA and anti-IgG-colloidal gold conjugate (5 nm), analyzed by electron microscopy shows specific
staining for PSA only in OMVs from wild-type bacteria but not B. fragilisDPSA. See also Figure S1.
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was ameliorated by oral administration of PSA-containing
vesicles (Figure 2C). TNBS colitis manifests in focal lesions
throughout the colon that mimic the pathology observed in
Crohn’s disease. Finally, clinical symptoms were evaluated by
a blinded pathologist to assess disease (Wirtz et al., 2007). While
all TNBS and DPSA-OMV treated animals were severely
affected, oral administration of WT-OMVs significantly amelio-
rated disease (Figure 2D). Moreover, when OMVs were adminis-
tered rectally (instead of orally) to themouse colon, animals were
protected from colitis (Figures S2D and S2E). We conclude
that PSA packaging into OMVs protects animals from the
pathological and immunological manifestations of experimental
colitis, and that OMVs from B. fragilis represent a candidate
therapy for IBD.
OMV-Associated PSA Induces Foxp3 and IL-10 from
CD4+ T Cells
Themucosal immune system constitutively surveys the intestinal
environment and DCs sample intestinal contents to coordinate
T cell reactions (Rescigno et al., 2001). Purified PSA adminis-Cell Hosttered orally to animals is associated with CD11c+ DCs in the
MLN (Mazmanian et al., 2005). To extend these studies to cell
culture, we show that vesicles were taken up by bone marrow-
derived DCs (BMDCs) regardless of PSA expression (Figure 3A
and Figure S3A). Confocal microscopy revealed that OMVs
(labeled with FITC) appeared as punctuate foci throughout the
cytoplasm of cells (Figure S3A). DCs rapidly internalized vesicles
in an actin-dependent manner, as treatment of cells with cyto-
chalasin D significantly inhibited vesicle uptake (Figure S3B).
Proportions of DC expressing activation markers (MHCII,
CD86) increased following internalization of OMVs regardless
of PSA expression (Figure 3B and Figure S3C), ruling out cell
stimulation differences between the two different vesicle
treatments.
As IL-10 production is known to prevent colitis by suppressing
unwanted inflammation (Maynard and Weaver, 2008), we exam-
ined if OMVs promote anti-inflammatory immune responses
in cell culture. BMDCs were treated with OMVs, washed, and
cultured with naive CD4+ T cells. WT-OMVs induced the expres-
sion of IL-10 during in vitro DC-T cell coculture, while minimal
IL-10 was detected from DCs alone. Addition of anti-CD3 to& Microbe 12, 509–520, October 18, 2012 ª2012 Elsevier Inc. 511
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Figure 2. OMVs Protect Animals from Experimental Colitis and Intestinal Inflammation in a PSA-Dependent Manner
(A)Weight loss in animals following the induction of TNBS colitis (day 0)measured as reduction from initial weight until day of sacrifice (day 4). All groups contained
at least four animals, with error bars indicating standard error (SEM). Results are representative of three independent trials. *p < 0.05; ***p < 0.001.
(B) Images of colons immediately following resection and quantification of length (indicated in the bar graph) from vehicle-treated (EtOH) and TNBS groups
(n = 4 animals/group). Error bars indicate SEM. Results are shown from three combined experiments where each was performed independently. ***p < 0.001.
NS, not significant.
(C) Images from hematoxylin and eosin (H&E)-stained colon sections representative of each treatment group.
(D) Colitis scores from animals assigned by a blinded pathologist (G.W.L) according to a standard scoring system (see the Experimental Procedures). Each
symbol represents an individual animal. Results are shown from three combined experiments, each performed independently. ***p < 0.001. NS, not significant.
See also Figure S2.
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the main source of IL-10 was from CD4+ T cells (Figure 3C).
Vesicles purified from B. fragilisDPSA induced significantly less
IL-10 than WT-OMVs, although an increase was observed over
media controls. IL-10 production by DCs is known to promote
CD4+IL-10+ T cell development both in vivo and in vitro
(O’Garra et al., 2004). Accordingly, we observed no increase in
IL-10 production when wild-type T cells were cocultured with
IL-10/ DCs following treatment with OMVs (Figure 3D),
showing that IL-10 expression by DCs is required to induce
IL-10 from CD4+ T cells.
CD4+CD25+ T cells that express the transcription factor
Forkhead box P3 (Foxp3) are an important regulatory T cell
(TREGS) subset shown to protect animals from inflammatory
and autoimmune diseases (Izcue et al., 2009). Recent studies
have shown that CD4+CD25+Foxp3+ TREGS can express
IL-10, and IL-10 production from TREGS is required to prevent
intestinal inflammation (Rubtsov et al., 2008). To determine the
source of IL-10 induced by OMVs, we purified CD4+CD25+
and CD4+CD25 T cells following coculture with DCs and
measured the expression of Foxp3 and IL-10 by qRT-PCR.
Remarkably, PSA containing OMVs significantly induced IL-10512 Cell Host & Microbe 12, 509–520, October 18, 2012 ª2012 Elsevexpression in the CD4+CD25+ TREG population, but not
from CD4+CD25 T cells (Figure 3E). Vesicles purified from
B. fragilisDPSA were unable to enhance IL-10 production
from either T cell population compared to media controls.
Expression of Foxp3 was increased exclusively in CD4+CD25+
T cells by OMVs in a PSA-dependent manner (Figure 3F).
Furthermore, flow cytometry revealed that WT-OMVs stimulated
increased IL-10 production from CD4+CD25+ T cells compared
to DPSA-OMVs, whereas vesicles with or without PSA induced
similar baseline levels of IL-10 from CD4+CD25 T cells
(Figure 3G).
We sought to determine if PSA could enhance the anti-inflam-
matory capacity of TREGS by measuring their function in cell
culture suppression assays. CD4+CD25 responder cells were
labeled with the intracellular dye CFSE (carboxyfluoresceinsuc-
cinimidyl ester), the fluorescence of which decreases propor-
tionally as cells proliferate (Figure 3H; No TREGS). Addition of
CD4+CD25+ TREGS suppresses cell division (Figure 3H; Media).
DCs were pulsed with OMVs, washed, and cultured with naive
CD4+ T cells; subsequently, CD4+CD25+ TREGS were purified
after coculture and added to CFSE-labeled responder CD4+
CD25 T cells; proliferation was measured by flow cytometry.ier Inc.
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Figure 3. Treatment of DCs with PSA-Containing OMVs Induces IL-10 Production and Foxp3 Expression from T Cells
(A) Flow cytometry (FC) analysis of OMV internalization by DCs. OMVs were labeled with FITC (fluorescein isothiocyanate) and incubated with cultured DCs for
various times. Cells were stained with anti-CD11c. Percentages show CD11c+OMV+ cell populations.
(B) FC plots of DCs incubated with WT-OMVs and DPSA-OMVs for various times and stained with anti-CD11c and anti-MHCII (major histocompatibility
complex II). Percentages show MHCII+ populations among CD11c+ cells.
(C) ELISA analysis for IL-10 production from culture supernatants of DCs or DC-T cell cocultures, where DCs were pulsed with OMVs for 18 hr, washed, and
incubated with or without splenic CD4+ T cells. Supernatants were collected at day 4 of culture. Media samples indicate DCs that were not pulsed with OMVs but
were otherwise treated identically. Anti-CD3 was added to some samples to demonstrate T cell-specific responses. Error bars indicate SEM from quadruplicate
samples. Results are representative of more than five independent trials. *p < 0.05; **p < 0.01.
(D) ELISA analysis of DC-T cell cocultures similar to (C), with IL-10/ DCs. Error bars indicate SEM from quadruplicate samples. Results are representative of
three independent trials. *p < 0.05; **p < 0.01. NS, not significant.
(E and F) Transcript levels of IL-10 (E) and Foxp3 (F) of RNA recovered from purified CD4+ T cell subsets following in vitro culture with DCs. Cocultures were set up
as in (C); on day 4, CD4+CD25+ and CD4+CD25 T cells were purified by magnetic bead separation (>95% purity) and RNA extracted for qRT-PCR. Relative
values were normalized to b-actin. Error bars indicate SEM. Results are shown from three combined experiments, each performed independently. *p < 0.05;
***p < 0.001. NS, not significant.
(G) FC histograms of IL-10 expression by CD4+ T cell subsets following 4 days of coculture with DCs treated with OMVs. Splenic CD4+ T cell were purified from
IL-10-GFPmice and stainedwith anti-CD4 and anti-CD25 following coculture, and IL-10 expressionwasmeasured byGFP expression. Percentages show IL-10+
populations among CD4+CD25+ and CD4+CD25 subsets. Results are representative of two independent trials.
(H) In vitro suppression of naive responder cells by purified CD4+CD25+ T cells following coculture with DCs treated with media (control), WT-OMVs, and DPSA-
OMVs. CD4+CD25 responder cells (effector cells; Teff) were pulsed with CFSE, incubated with TREGS, and stimulated with anti-CD3 and APC (CD4
+ T cell-
depleted splenocytes) for 3 days. Cell proliferation wasmeasured by FC as a function of CFSE dilution. TREG:Teff ratios are indicated, and percentages show total
proliferating cells. No TREG, CD4
+CD25 cells only. Numbers above peaks represent number of cell divisions. Results are representative of three independent
trials. See also Figure S3.
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Microbiota Molecules Program Tolerogenic DCsTREGS recovered from conditions with WT-OMV-treated DCs
displayed significantly enhanced suppressive capacity com-
pared to CD4+CD25+ T cells treated with DPSA-OMVs (Fig-
ure 3H and Figure S3D). Incubation of in vitro suppression
cultures with a neutralizing anti-IL-10 receptor antibody partially
abrogated TREG function induced by WT-OMVs but had no
effect on DPSA-OMV-stimulated TREGS (Figure S3E). Collec-
tively, we conclude that OMVs specifically induce functional
TREGS in cell culture, and that the absence of PSA from OMVs
abrogates the ability of B. fragilis vesicles to promote TREG
activity by DCs.Cell HostToll-like Receptor 2 on DCs Is Required to Sense
OMV-Associated PSA
Microbial ligands are detected by pattern recognition receptors
(Medzhitov, 2007), and PSA is sensed by TLR2 (Wang et al.,
2006). Unlike other microbial molecules, PSA promotes an
anti-inflammatory response upon TLR2 signaling (Round et al.,
2011). Innate immune cells (such as DCs) have been widely
recognized for their expression of TLRs and their central role in
alerting the innate and adaptive immune systems to microbial
infection. We recently reported that TLR2 on CD4+ T cells
responds to purified PSA to promote TREG function (Round& Microbe 12, 509–520, October 18, 2012 ª2012 Elsevier Inc. 513
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Figure 4. TLR2 on DCs Is Required to Sense OMV-Associated PSA and Induces Genes Specific for OMVs
(A) ELISA analysis of DC-T cell cocultures similar to Figure 3C from WT and TLR2/ DCs. SEA, staphylococcal enterotoxin A. Error bars indicate SEM from
quadruplicate samples. Results are representative of three independent trials. *p < 0.05. NS, not significant.
(B) Pie chart showing the number of upregulated genes (red) and downregulated genes (green) upon stimulation with PSA-containing OMVs during in vitro culture
with CD11c+ BMDCs, using a Whole Mouse Genome Microarray analysis. Unaffected genes (blue). Only genes p < 0.01 and fold change >2 were used for
subsequent analysis.
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Microbiota Molecules Program Tolerogenic DCset al., 2011). However, a role for TLR2 expression by innate
immune cells during OMV recognition remains unknown. To
test the requirement for DC-specific TLR2 in PSA recognition,
we treated WT and TLR2/ DCs with OMVs and subsequently
cocultured DCs with CD4+ T cells. Compared to wild-type
DCs, the absence of TLR2 (DCs from TLR2/ animals) almost
completely inhibited IL-10 production in response to vesicles
(Figure 4A). TLR2/ DCs have no defect in OMV uptake (Fig-
ure S4A). Both TLR2-sufficient and -deficient DCs responded
equally to superantigen (SEA) stimulation, demonstrating
a specific defect in PSA sensing, not a general lack of T cell acti-
vation by TLR2/ DCs. In addition, when TLR2/ T cells were
cultured with OMV-pulsed WT DCs, production of IL-10 was
unaffected (Figure S4B). When OMVs were added continuously
to DC-T cell cocultures (thus both cell types were exposed to
OMVs), TLR2 deletion on DCs led to decreased IL-10 induction
(Figure S4C). Furthermore, direct treatment of purified CD4+
T cells with PSA-containing OMVs resulted in no IL-10 upregula-
tion, unlike stimulation with purified PSA, which activated T cells
in a TLR2-dependent manner as previously shown (Figure S4D)
(Round et al., 2011). Therefore, while purified CD4+ T cells can
respond directly to PSA, immune responses to OMV delivery of
PSA require DC, and not T cell, expression of TLR2. Using this
information, we sought to identify cellular factors involved in
PSA-specific, TLR2-specific signaling by DCs.
TLR2 Signaling on DCs Induces OMV-Specific Gene
Expression
OMVs fromGram-negative bacteria have been shown to contain
numerous TLR ligands, including lipopolysaccharide (LPS), lipo-
proteins, peptidoglycan, and bacterial DNA (Beveridge, 1999).
These molecular patterns are recognized by DCs to drive proin-
flammatory reactions. PSA is a microbial molecule that induces
immune tolerance. To differentiate between the contributions
of PSA and other TLR ligands contained within vesicles, we per-
formed global gene expression profiling, comparing mRNA
levels induced by WT-OMVs and DPSA-OMVs in a TLR2-
specific fashion. Using microarray analysis, 4,712 target probes
representing mouse transcripts showed expression changes
following treatment of DCs with OMVs (Figure 4B). The vast
majority of these genes were classified as immune related by
the GO Biological Process enrichment and the KEGG Pathway
enrichment algorithms (Figure 4C). Approximately two-thirds of
the genes were either up- or downregulated similarly by both
WT-OMVs and DPSA-OMVs, representing PSA-independent
transcript changes within DCs (Figures 4D and 4E; blue shaded
regions). Of the remaining one-third (roughly 1,200), which
corresponds to PSA-dependent expression changes, the vast
majority (98%) of genes were regulated in a TLR2-dependent
fashion (Figure 4E). We currently do not know of other signaling
molecules that sense PSA, and further studies are needed to(C) Gene ontology analysis of changes in gene expression levels in BMDCs for v
(D) Heatmap analysis of gene expression in BMDCs from either wild-type or TLR2
are either upregulated or downregulated in a PSA-dependent manner and that t
(E) Pie charts show that the majority of the genes in BMDCs that respond to PSA
(F) List of select genes of highest fold change of expression level upon OMV stim
(G) qRT-PCR analysis of the expression level of genes listed in (F) identified and
TLR2-dependent manner from purified CD11c+ BMDCs. Results are representat
Cell Hostvalidate the few transcripts that appear to be regulated inde-
pendently of TLR2. However, a list of the top 12 genes that dis-
played greatest PSA-specific, TLR2-specific changes again
yielded several molecules known to have immune functions (Fig-
ure 4F). Of these, transcriptional analysis by qRT-PCR verified
the microarray results for six genes, which showed a pattern of
being upregulated by WT-OMVs and dependent on TLR2
expression (Figure 4G). Thus, by virtue of delivering PSA to
DCs, OMVs signal through TLR2 to induce a highly specific
gene expression profile.
DCs Require Gadd45a for Induction of IL-10
Downstream of TLR2, factors involved in the intracellular
signaling pathway(s) that respond to PSA remain completely
unknown. Based on its reported role in the immune system, we
assessed the function of Gadd45a, whose expression by DCs
has been shown to promote T cell responses (Jirmanova et al.,
2007). Gadd45a was induced by OMVs in a PSA-specific,
TLR2-specific manner (see Figure 4G). Gadd45a/ DCs have
no defect in OMV internalization (Figure S5A). Coculture of
Gadd45a/ DCs with WT CD4+ T cells resulted in reduced
IL-10 production compared to WT DCs treated with WT-OMVs
(Figure 5A). The level of IL-10 expression upon coculture of
Gadd45a/ DCs and CD4+ T cells was identical following
treatment with either WT-OMVs or DPSA-OMVs. IL-10 produc-
tion from BMDCs alone treated with OMV was not detectable
by ELISA (see Figure 3C); thus, using qRT-PCR analysis, we
found that IL-10 expression by BMDCs was increased by
WT-OMVs, whereas Gadd45a/ DCs displayed reduced IL-10
expression when treated with WT-OMVs or DPSA-OMVs
(Figure 5B). Gene expression profiling had identified several
other genes that were coregulated with Gadd45a (see Figures
4F and 4G). Of these, BpiI2 and Chac1 are downstream of
Gadd45a signaling as their expression is lost in Gadd45a/
DCs following treatment with OMVs (Figure S5B). Gadd45a
thus appears to be a central signaling component of the TLR2
response to OMVs by DCs.
DCs Mediate Protection from Colitis through
a Requirement for Gadd45a
Colonization of animals with B. fragilis or treatment with PSA
ameliorates experimental colitis (Mazmanian et al., 2008; Round
and Mazmanian, 2010). However, the role of DCs during PSA-
mediated protection from disease remains unknown. We first
tested OMVs in Gadd45a/ animals induced for TNBS colitis.
While OMV restored the colon length and suppressed proinflam-
matory cytokine production in Gadd45a+/ (wild-type) litter-
mate controls, Gadd45a/ mice were not protected (Figures
S5C and S5D). To demonstrate whether DCs require Gadd45a
for in vivo PSA activity, we incubated BMDCs with vesicles
and transferred cells into mice that were induced for TNBSarious biological processes or pathways.
/ animals upon OMV stimulation reveals that approximately 30% of the genes
he majority of the genes are TLR2 dependent.
are dependent on TLR2.
ulation in a PSA- and TLR2-dependent manner.
confirmed six genes that are significantly upregulated by OMVs in a PSA- and
ive of three independent experiments. See also Figure S4.
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Figure 5. Gadd45a on DCs Is Required for In Vitro IL-10 Production and Protection from Colitis by OMVs
(A) ELISA analysis of DC-T cocultures similar to Figure 3C, but also includingGadd45a/DCs. Error bars indicate SEM from quadruplicate samples. Results are
representative of three independent trials. *p < 0.05; **p < 0.01. NS, not significant.
(B) qRT-PCR analysis of IL-10 transcript levels from either WT orGadd45a/ BMDCs after 16–18 hr incubation with OMVs in vitro. Error bars indicate SEM from
triplicate samples. Results are representative of three independent trials. **p < 0.01. NS, not significant.
(C) Colitis scores from DC recipient animals induced for TNBS colitis. Each symbol represents an individual animal. Results are shown from two combined
experiments, each performed independently.
(D) Colon length frommice, at day 2 following TNBS treatment. Each symbol represents an individual animal. Error bars indicate SEM from eight animals. Results
are shown from two combined experiments, each performed independently. *p < 0.05; ***p < 0.001. NS, not significant.
(E) Cytokine analysis by qRT-PCR of RNA recovered from whole colon. Each symbol represents an individual animal. Error bars indicate SEM from eight animals.
Results are shown from two combined experiments, each performed independently. See also Figure S5.
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Microbiota Molecules Program Tolerogenic DCscolitis. WT-OMV-treated DCs protected animals from disease
compared to control (PBS) treated cells (Figure 5C). However,
treatment of Gadd45a/ DCs with OMVs prior to transfer into516 Cell Host & Microbe 12, 509–520, October 18, 2012 ª2012 Elsevwild-type mice resulted in disease scores similar to untreated
cells (last column of Figure 5C), demonstrating that Gadd45a is
required by DCs for PSA-mediated protection. Representativeier Inc.
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Microbiota Molecules Program Tolerogenic DCshistopathology is shown in Figure S5E. Accordingly, reduction in
colon length is rescued by OMV treatment of WT, but not
Gadd45a-deficient, DCs (Figure 5D). Finally, we analyzed proin-
flammatory molecules within intestinal tissues of TNBS colitis-
induced animals following DC transfer. The cytokines IFNg,
IL-6, and TNFa were reduced in the colon following transfer of
WT DCs incubated with OMVs (Figure 5E). Transfer of
OMV-treated Gadd45a/ DCs into animals resulted in cytokine
and chemokine levels as high as those in untreated DCs (last
column of Figure 5E), although these trends did not reach statis-
tical significance. Collectively, these findings show that OMVs
promote tolerogenic DC function during protection from colitis
and further identify Gadd45a is a factor required for PSA activity,
revealing a previously unknown signaling pathway by which the
human mutualist B. fragilis mediates immunologic health.
DISCUSSION
Molecular Communication between the Microbiota
and the Immune System
Bacteria shape diverse environments on land, in the oceans, and
within plants and animals; often, these processes are mediated
by secretion of bacterial molecules. Regarding interactions
with mammals, decades of research has uncovered molecules
produced by pathogens that promote bacterial invasion into
tissues and cells, nutrient acquisition, and subversion of the
immune system. We know of numerous mechanisms by which
virulence factors are secreted or delivered to mammalian
targets. Only recently has it become appreciated that symbiotic
bacteria also establish molecular communication with mam-
mals. The archetypal symbiosis factor of the human microbiota
is PSA fromBacteroides fragilis, which ameliorates inflammatory
disease in animals by inducing immunologic tolerance (Lee and
Mazmanian, 2010). However, it has remained unknown how
PSA is delivered to the immune system. The studies described
herein illustrate that OMVs released from the bacterial surface
are sufficient to mediate interkingdom interactions between
B. fragilis and the immune system by delivering PSA to DCs.
Oral treatment of mice with OMVs prevents experimental colitis,
whereas vesicles from B. fragilisDPSA are unable to protect
animals from wasting disease, histopathology, and proinflam-
matory cytokine production. As attempts to delete OMVs
from bacteria have thus far been unsuccessful, as they may be
necessary for viability (Deatherage et al., 2009; McBroom and
Kuehn, 2007), the in vivo relevance of B. fragilis OMVs during
intestinal colonization requires further investigation. However,
our work reveals a paradigm by which a beneficial bacterium
of the human microbiota selectively delivers a microbial mole-
cule to its host. Future studies will aim to understand how other
components of B. fragilis OMVs interact with the mammalian
immune system.
OMVs Mediate Immune Tolerance through Activation
of Dendritic Cells
In response to sampling both self and foreign antigens, DCs
interact with a variety of immune cells to coordinate diverse bio-
logical responses. The presentation of microbial molecules from
pathogens to CD4+ T cells is a critical component of a productive
immune response during infection. Conversely, antigens of theCell Hostmicrobiota must be either ignored or actively tolerated during
long-term colonization to prevent deleterious reactions that
may adversely affect both microbes and mammals. Indeed, it
is believed that a critical feature of IBD is uncontrolled immune
reactivity to the microbiota. Our laboratory has previously
shown that PSA induces immunologic tolerance through IL-10-
producing Foxp3+ regulatory T cells (TREGS), a process that
protects animals from colitis and promotes colonization by
B. fragilis (Round et al., 2011; Round and Mazmanian, 2010).
Here we show that OMVs internalized by DCs induce tolerogenic
DCs that produce IL-10, which in turn drives the development of
IL-10-producing TREGS. In contrast, OMVs from B. fragilisDPSA
do not promote TREGS. Thus, unlike immunity that results
from recognition of microbial molecules from pathogens,
PSA programs DCs to adopt an anti-inflammatory profile
leading to T cell-mediated tolerance and protection from exper-
imental colitis.
Recently, it was shown that intestinal colonization of animals
with B. fragilis prevents and treats experimental autoimmune
encephalomyelitis (EAE), an animal model for human MS
(Ochoa-Reparaz et al., 2010a, 2010b). Both EAE and MS involve
inflammation in the central nervous system (CNS). How does
PSA, a symbiosis factor produced in the gut, mediate protection
from immunity in the brain and spinal cord of animals? Mice pro-
tected from disease display an increase in the proportions of
CD11c+CD103+ DCs, a subset that is known to promote TREG
differentiation (Ochoa-Reparaz et al., 2010a, 2010b). Interest-
ingly, increased CD103+ DCs and Foxp3+ TREG proportions
are only observed in the cervical lymph nodes that drain the
CNS, but not in other systemic compartments. It is currently
unknown if the gut is the site of tolerogenic DC induction fol-
lowed by cell migration to the CNS, or if PSA somehow activates
DCs outside the intestine. Further, it will be interesting to know
the subset of DCs that respond to PSA/OMVs. As tolerogenic
DCs promote TREG development, and TREGS have been shown
to suppress inflammation in many tissues of the body, it is
conceivable that PSA may represent a therapy for immunologic
diseases beyond IBD and MS.
TLR2 Signaling by DCs Is Required for OMV Sensing
Immune cells recognize microbial ligands through pattern recog-
nition receptors to initiate immunologic responses. Previous
studies have identified TLR2 as being required for PSA-mediated
induction of interferon (IFNg) (Wang et al., 2006), as well as IL-10
production from TREG cells (Round and Mazmanian, 2010).
Furthermore, TLR2-deficient animals are not protected from
TNBS colitis by PSA treatment (Round and Mazmanian, 2010).
Our studies now reveal that TLR2 expression by DCs is neces-
sary for the induction of anti-inflammatory responses by
OMVs. This phenotype is largely dependent on PSA, although
OMVs contain other molecules (perhaps lipoproteins) that also
increase IL-10 expression through TLR2 (see Figure 4A). In
contrast, we have previously shown that purified PSA is able to
directly induce IL-10 from CD4+ T cells in the absence of DCs.
The DC-dependent pathway described here is specific for
OMVs, as treatment of T cells alone with OMVs (containing
PSA) is unable to promote IL-10 production from CD4+ T cells,
unlike purified PSA. Furthermore, TLR2 deletion on DCs abro-
gates IL-10 production during in vitro culture with OMVs. The& Microbe 12, 509–520, October 18, 2012 ª2012 Elsevier Inc. 517
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colonization by B. fragilis remains unresolved, and further
studies involving in vivo metabolic labeling of PSA are required
to distinguish when, where, and how each cell type ‘‘sees’’
PSA. However, we speculate the possibility that DCs internalize
PSA associated with OMVs, which traffic through the endocytic
pathway to contact T cells at the immunologic synapse. This
notion is supported by evidence that PSA is presented to
CD4+ T cells by major histocompatibility complex (MHC II)
following internalization and processing in the endosome.
Perhaps deletion of TLR2 on T cells abrogates PSA recognition
at the immunologic synapse following initial association of DCs
with OMVs. Thus, both cell typesmay require TLR2, and addition
of purified PSA directly to T cells bypasses the requirement for
DC expression of TLR2 (Round et al., 2011). Other models are
conceivable as well, and the details of the mechanism by which
the immune system responds to anti-inflammatory microbial
ligands are currently being addressed. What is clear from our
results is that PSA, in the context of OMVs, directly activates
DCs and not T cells, in a process that requires TLR2. The conse-
quence of this interaction leads to the induction of tolerogenic
DCs that enhance Treg function and promote protection from
inflammatory disease.
Identification of Gadd45a in the PSA Signaling Pathway
Following internalization into DCs and engagement of TLR2,
OMVs initiate a gene expression program that results in IL-10
production by DCs. Although it is known that the outcome of
PSA sensing by the immune system is TREG induction, nothing
is known about the intracellular signaling pathway(s) activated
by PSA within DCs. We analyzed the gene expression profile of
DCs treated with OMVs to uncover factors that are expressed
in a PSA-dependent, TLR2-dependent manner. Of the handful
of candidates, we focused on Gadd45a due to its known role
in immune responses. In addition to a function in stress
responses and cell-cycle control, Gadd45a has been shown to
affect T cell activation by inhibiting the alternative p38 pathway
in CD4+ T cells (Salvador et al., 2005). More recently, Gadd45a
expression by DCs was implicated in Th1 polarization in
response to Toxoplasma gondii antigen stimulation (Jirmanova
et al., 2007). Levels of the Th1 skewing cytokine IL-12 are
reduced in Gadd45a/ DCs, resulting in a non-T cell intrinsic
reduction in IFNg+ T cells. We show that Gadd45a is upregulated
upon OMV stimulation in a TLR2-specific fashion, and that
absence of Gadd45a in OMV-treated DCs leads to a defect in
IL-10 production. Furthermore, this results in a lack of IL-10
expression from CD4+ T cells cocultured with Gadd45a/
DCs. Transfer of DCs treated with OMVs into wild-type animals
ameliorates TNBS colitis, demonstrating the protective effects
of PSA directly on DCs. Transfer of OMV-treated DCs deficient
in Gadd45a results in no protection from the histopathologic
damage and cytokine production associated with colitis,
revealing that PSA signaling in DCs requires Gadd45a. Intrigu-
ingly, Gadd45a-deficient animals die at late ages from lupus-
like autoimmunity (Salvador et al., 2002), a pathology that has
been linked to defective Treg function (Buckner, 2010). Collec-
tively, these results suggest a model whereby PSA from OMVs
activates TLR2 to induce expression of Gadd45a, which in turn
modulates intracellular signaling cascades to promote tolero-518 Cell Host & Microbe 12, 509–520, October 18, 2012 ª2012 Elsevgenic DC function and Treg development during protection
from autoimmune and/or inflammatory disease.
Perspective
Eons of coevolution have formed an inextricable connection
between mammals and our microbiota. With over 100-fold
more unique genes in the microbiome than the human genome,
symbiotic bacteria possess the vast potential to produce mole-
cules, destined for their host, which mediate various biological
processes. We reveal that B. fragilis actively delivers PSA via
OMVs, uncovering a previously unrecognized mechanism by
which the immense molecular coding potential of the micro-
biome can be utilized during mutualism. Sustained, lifelong
molecular communication between the microbiota and mam-
mals bridges the boundaries between kingdoms of life, and
supports the notion that animals may be viewed as holobionts:
a single unit of evolutionary selection comprised of a host and
its associated microbes (Rosenberg et al., 2009).
EXPERIMENTAL PROCEDURES
Bacterial Strains and Culture Conditions
Bacteroides fragilis strain NCTC9343 was obtained from the American Type
Culture Collection, and B. fragilisDPSA has been described (Coyne et al.,
2001). Bacteria were grown either in brain heart infusion (BHI) broth (BDBiosci-
ences) or a minimum medium containing 8 g glucose, 1% FBS, 0.5 mg hemin,
and 0.5 mg/ml vitamin K in 1 L of RPMI (Invitrogen).
Mice
C57BL/6 and BALB/c mice were purchased from Taconic Farms. TLR2
knockout and IL-10 knockout mice were purchased from Jackson Laborato-
ries. Gadd45a knockout mice were maintained in an NCI pathogen-free animal
facility. IL-10-eGFP mice (Vert-X mice) have been described previously (Sun
et al., 2009). Foxp3-eGFP mice were obtained from Talal A. Chatila (University
of California, Los Angeles) (Lin et al., 2007). All procedures were performed in
accordance with the guidelines and the approved protocol from the Institu-
tional Animal Care and Use Committee at California Institute of Technology.
OMV Purification and Labeling
B. fragilisOMV isolation was adapted from a previously described protocol for
the preparation of OMVs from Escherichia coli (Horstman and Kuehn, 2002).
Briefly, EDL-enrichedB. fragilis (Patrick and Reid, 1983) was grown in custom-
ized minimal media. OMVs were recovered from the bacteria-free culture
supernatant by centrifugation. FITC-labeled OMVs were prepared as previ-
ously described (Kesty and Kuehn, 2004).
Electron Microscopy of Bacterial Ultrathin Sections
Ultrathin sections of EDL-enriched B. fragilis were prepared as previously
described (Patrick et al., 1996). For immunogold labeling, purified OMVs
were applied to formvar/carbon coated gold grids (EMS). Samples were
blocked in 10% FBS for 10 min after 5 min incubation in 0.12% glycine. After
blocking, samples were incubated with anti-PSA. Secondary anti-IgG conju-
gated with 5 nm gold was applied to the samples for 20 min and washed. After
labeling, samples were fixed in 1% glutaraldehyde for 5 min and washed
extensively by transferring grids to drops of PBS and H2O. Contrast staining
was performed by placing the grids on drops of 3%–5% uranyl acetate in
2%methylcellulose for 10 min on ice. Samples covered by a thin film of meth-
ylcellulose were removed from loop and used for visualization by TEM.
Chemical-Induced Experimental Colitis
BALB/c mice were orally treated with PBS, WT-OMV (5 mg), or DPSA-OMV
(5 mg) every other day for 1 week before TNBS administration. Mice were anes-
thetized with isofluorane, and rectal administration of 2% TNBS (in 50% EtOH,
Sigma) was applied through a 3.5F catheter (Instech Solomon; SIL-C35) as
previously described (Wirtz et al., 2007). For DC transfer-TNBS experiments,ier Inc.
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for 16–18 hr. 2 3 106 cells were intraperitoneally injected into each recipient
(C57Bl/6) mouse 2 hr before TNBS (125 mg/kg) administration.
Tissue Pathology Analysis
Mouse colons were fixed in neutral buffered 10% formalin (ScyTek Laborato-
ries), embedded in paraffin, sectioned, and stained by Pacific Pathology (San
Diego, CA). Colitis scores for each colon section were evaluated in a blinded
fashion by a veterinary pathologist (G.W.S.) using a standard scoring system
(Wirtz et al., 2007): 0, no signs of inflammation; 1, low level of inflammation;
2, low level of leukocytic infiltration; 3, high level of leukocytic infiltration,
high vascular density thickening of colon wall; 4, loss of goblet cells, high
vascular density, thickening of colon wall. Histology images were taken using
light microscopy at 203 magnification.
Colon Lamina Propria Lymphocyte Isolation and Intracellular
Cytokine Staining
Performed as previously described (Round et al., 2011; Round and Mazma-
nian, 2010). Full-length colon was dissected, and luminal contents were care-
fully flushed. Colon epithelium was dissociated, digested with collagenase D
(0.5 mg/ml), dispase (3 units/ml), and DNase I (0.5 mg/ml). Finally, a 40%–
80% Percoll gradient was used to isolate lamina propria lymphocytes
(LPLs). Intracellular cytokine staining (ICCS) was performed on LPLs that
were restimulated in vitro with PMA/ionomycin in the presence of golgi-plug
for 4.5 hr, according to manufacturer’s protocol (BD Biosciences).
In Vitro BMDC-T Cell Coculture
Performed as previously described (Round et al., 2011; Round and Mazma-
nian, 2010). Briefly, DCs were differentiated from bone marrow. OMV-pulsed
BMDCs (10 mg/ml OMVs, 1 3 105 cells/ml, 12–24 hr) were incubated with
splenic CD4+ T cells. BMDCs, for the OMV uptake assay or activation assay,
were collected and blocked in 5% mouse serum for 30 min on ice. Cells
were stained with specific antibodies for 30 min on ice and washed twice
with FACS buffer at 4C. Cells from in vitro BMDC-T cell coculture were
blocked, and stained similarly except that the cells were restimulated using
PMA/ionomycin for 4 hr before collecting. All FC was performed with BD
FACSCalibur, and results were analyzed using the FlowJo software (BD
Biosciences). In some experiments, BMDCs were pretreated with 5 mM Cyto-
chalasin D for 1 hr before adding FITC-labeled OMVs.
In Vitro Suppression Assay
CD4+CD25+Treg cells purified from BMDC-T cell cocultures using magnetic
microbeads (Miltenyi Biotec). CD4-depleted mouse splenocytes treated with
Mitomycin C (Sigma) were used as APCs (1 3 105 cells/ml). CD4+CD25
responder T cells directly purified from mouse spleen were pulsed with
CFSE for 10 min at 37C, followed by first wash with PBS and a second
wash with culture media, and used immediately (5 3 105 cells/ml), referred
to as effector T cells (Teff). This assay was conducted in round-bottom
96-well plates with an addition of 5 mg/ml of anti-CD3 (eBiosciences) in
200 ml. Teff:Treg ratio was titrated and cells were collected after 2–3 days of
culture for FACS analysis. Anti-IL-10R (20 mg/ml, R&D Systems) was added
as indicated in the results.
Microarray Hybridization and Data Analysis
RNA samples (1 mg total RNA) fromBMDCswere labeled with fluorescent dyes
using the Quick Amp Labeling Kit (Agilent). Microarray (AgilentWhole Mouse
Genome chip) hybridizations (65C for 16 hr) and washes were performed
with Agilent reagents following standard protocols. Microarrays were analyzed
using an Agilent DNA Microarray Scanner G2565CA, and data were acquired
using Agilent’s Feature Extraction Software version 10.1.1.1. Significant genes
were selected based on p < 0.01 and fold change >2.0. For enrichment
analysis of biological process ontology, probe lists were analyzed in DAVID
(The Database for Annotation, Visualization and Integrated Discovery annota-
tion tools [http://david.abcc.ncifcrf.gov/]) and selected based on p < 0.01.
Statistical Analyses
Student’s t test and one-way ANOVA were applied for pairwise comparisons
and comparisons among greater than two groups, respectively. SignificantCell Hostdifferences among groups detected by ANOVA were analyzed using
Newman-Keuls test as the post-hoc test to identify groups exhibiting statisti-
cally significant differences.
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